Cesca Therapeutics was issued a patent for regenerative cell therapy in its clinical studies. The company partially blames the patent for the annual loss in revenue, according to the Sacramento Business Journal.
Here are five notes:
1. The company has recently devised regenerative therapies utilizing marrow and blood products.
2. The company reports a series of losses including losing $4.8 million in its fiscal third quarter, compared to a loss of $1.9 million during the same quarter ending March 31 in 2014.
3. The company lost $12.5 million in its first three quarters this year, an increase from a loss of $5.8 million in the same period last year.
4. Cesca's revenue was $4 million this quarter, flat from the same quarter in the previous year.
5. The company's revenue through the last nine months was $12.3 million this year compared to $12.2 million for the same period in 2014.
For more news:
Orthopedic surgeon to know: Dr. Frank Petrigliano of UCLA Health
Limb length discrepancies leading to pain — 5 things to know
Wellmont Orthopedic Residency Program sees 1st group of graduates: 5 quick notes